BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- treatment
Top Cited Papers
Open Access
- 1 October 2005
- Vol. 60 (10) , 800-805
- https://doi.org/10.1136/thx.2005.046797
Abstract
Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor α (anti-TNF-α) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.Keywords
This publication has 15 references indexed in Scilit:
- High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapyClinical Gastroenterology and Hepatology, 2004
- Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapyArthritis & Rheumatism, 2004
- Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.2002
- Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical TrialAnnals of Internal Medicine, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Published by Massachusetts Medical Society ,2001
- New drugs for the treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy, 2000
- The treatment of tuberculosis in HIV-infected personsAIDS, 1999